Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $82.37M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.81M
Average 0.75M
NKTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Nkarta, Inc.NASDAQ: NKTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $1.9M fell 33.0% year over year, ahead of the -49.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 0.1% from the prior quarter. Over 3 fiscal years it compounded at -20.2% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -33.0% holds above the trailing-twelve-month pace of -49.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 8.56M USD
- Year-over-year change
- -48.8%
- 4-year CAGR
- -12.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.56M | -48.8% |
| FY2024 | 2024-12-31 | 16.73M | -2.7% |
| FY2023 | 2023-12-31 | 17.2M | +2.0% |
| FY2022 | 2022-12-31 | 16.86M | +16.6% |
| FY2021 | 2021-12-31 | 14.46M | — |
Stock-Based Compensation vs competitors
How NKTX compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -49.8% is the lowest of 8, against a peer median of -4.1%.
- Over three fiscal years its annual growth of -20.2% compares with a peer median of +15.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $27.69M USD | +218.3% | +20.9% | — | |
| LTM Mar 2026 | $21.47M USD | -43.3% | -31.8% | 340.0% | |
| LTM Mar 2026 | $21.22M USD | -43.4% | -16.7% | 115.2% | |
| LTM Mar 2026 | $10.03M USD | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $7.82M USD | +99.9% | +15.9% | — | |
| LTM Mar 2026 | $7.62M USD | -49.8% | -20.2% | — | |
| LTM Mar 2026 | CHF 4.21M CHF | -4.1% | -4.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $3.05M USD | +83.8% | +67.0% | — |
| Peer median (excluding NKTX) | — | -4.1% | +15.9% | 227.6% | |
Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Depreciation & Amortization | 1.76M | 2.64M | 5.87M | 2.24M | 4.61M |
| Deferred Income Tax | 3.24M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.46M | 16.86M | 17.2M | 16.73M | 8.56M |
| Change in Working Capital | (1.64M) | 33.74M | 10.93M | (12.16M) | (435K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.79M | 2.76M | 4.22M | (4.47M) | 2.46M |
| Other Working Capital | (4.44M) | 30.98M | 6.7M | (7.69M) | (2.9M) |
| Other Non-Cash Items | 337K | 3.61M | (2.65M) | 2.29M | 2.65M |
| Operating Cash Flow | (67.93M) | (57M) | (86.16M) | (99.7M) | (88.7M) |
| Capital Expenditures | (5.03M) | (47.11M) | (28.15M) | (4.41M) | (1.21M) |
| Acquisitions (Net) | (37.56K) | 137.58K | 0 | 0 | 0 |
| Purchases of Investments | (227.28M) | (385.89M) | (260.23M) | (406.38M) | (238.57M) |
| Sales of Investments | 264.84M | 248.31M | 367.4M | 281.23M | 340.09M |
| Other Investing Activities | 37.56K | (137.58K) | 0 | 0 | 0 |
| Investing Cash Flow | 32.53M | (184.69M) | 79.02M | (129.56M) | 100.32M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.2M | 217.17M | 691K | 225.07M | 141K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.84M | 0 | 1.01M | 0 |
| Financing Cash Flow | 1.2M | 219.01M | 691K | 226.08M | 141K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (34.19M) | (22.68M) | (6.45M) | (3.17M) | 11.76M |
| Free Cash Flow | (72.95M) | (104.11M) | (114.31M) | (104.11M) | (89.91M) |
Nkarta, Inc.
NASDAQ:NKTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.